Oncopeptides
Sweden - Stockholm
BiotechnologyFocus: Cancer Treatments
Oncopeptides is a life sciences company focused on Cancer Treatments.
Oncology
Funding Stage
PUBLIC
Open Jobs
5
Pipeline & Clinical Trials
Melphalan Flufenamide
Relapsed and/or Refractory Multiple MyelomaClinical Trials (1)
NCT04534322Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma
N/AMelphalan-Flufenamide
AL AmyloidosisClinical Trials (1)
NCT04115956A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
Phase 1Phase 1
Clinical Trials (1)
NCT04918511A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma
Phase 1Phase 1/2
Clinical Trials (1)
NCT01897714Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients
Phase 1/2Melphalan flufenamide
Multiple MyelomaClinical Trials (1)
NCT03481556Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
Phase 1/2Melphalan flufenamide
Multiple MyelomaMelflufen
Renal ImpairmentClinical Trials (1)
NCT03639610PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function
Phase 2Melphalan
RRMMClinical Trials (1)
NCT04412707A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients
Phase 2Melflufen
Relapsed Multiple MyelomaClinical Trials (1)
NCT04649060Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma
Phase 3Melflufen
Multiple MyelomaClinical Trials (1)
NCT03151811A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide
Phase 3Open Jobs (5)
Interview Prep Quick Facts
Founded: 2000
Portfolio: 9 clinical trials
Open Roles: 5 active jobs